第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。日前，官网已公布摘要题目，肿瘤瞭望特将Late-Breaking Oral Presentations、General Session、Rapid Fire、Poster Spotlight Sessions等环节口头报告内容进行整理，敬请关注！
编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。日前，官网已公布摘要题目，肿瘤瞭望特将Late-Breaking Oral Presentations、General Session、Rapid Fire、Poster Spotlight Sessions等环节口头报告内容进行整理，敬请关注！
Late-Breaking Oral Presentations
时间：12月10日6:00–7:00 pm
地点：Stars at Night 1-2
主持人：Rita Nanda，University of Chicago Medicine，Chicago，Illinois
LB1-01:Long-term effects of the omission of immediate surgery in operable breast cancer，or reduction of surgical extent:patient-level meta-analysis of the four randomised trials among 2，514 women.
可手术乳腺癌中省略即刻手术或缩小手术范围的长期影响：基于2514名女性的四项随机试验患者层面的荟萃分析
讲者：Robert Hills，University of Oxford，Oxford，United Kingdom
LB1-02:MARGOT/TBCRC052:A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab(TMP)vs paclitaxel/trastuzumab/pertuzumab(THP)in patients(pts)with stage II-III HER2+breast cancer.
MARGOT/TBCRC052：一项随机II期临床试验，比较II-III期HER2阳性乳腺癌患者中新辅助治疗帕妥珠单抗/马吉妥昔单抗/紫杉醇（TMP）vs帕妥珠单抗/曲妥珠单抗/紫杉醇（THP）的疗效
讲者：Adrienne Waks，Dana-Farber Cancer Institute，Boston，Massachusetts
LB1-03:Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+metastatic breast cancer and indication for chemotherapy-PADMA study.
PADMA研究：比较高危HR+/HER2-转移性乳腺癌女性患者一线ET联合哌柏西利vs标准单药化疗的随机III期试验的主要结果
讲者：Sibylle Loibl，German Cooperative Group，Neu-Isenburg，Germany
LB1-04:Efficacy and safety of trastuzumab deruxtecan(T-DXd)vs physician’s choice of chemotherapy(TPC)by pace of disease progression on prior endocrine-based therapy:additional analysis from DESTINY-Breast06.
基于既往内分泌治疗的疾病进展速度，比较德曲妥珠单抗（T-DXd）vs医生选择的化疗（TPC）的疗效与安全性：来自DESTINY-Breast06的额外分析
讲者：Aditya Bardia，UCLA David Geffen School of Medicine，Los Angeles，California
LB1-05:ROSC(Neo)adjuvant nab-PAC weekly vs sb-PAC q2w，followed by EC q2w，in genomically or clinically high-risk HR+/HER-early breast cancer according to ET-response:final survival results from the WSG ADAPT-HR+/HER2-chemotherapy-trial.
在遗传或临床高危HR+/HER2-早期乳腺癌中，根据ET反应（新）辅助nab-PAC周疗vs每2周1次sb-PAC，随后每2周1次EC：WSG ADAPT-HR+/HER2-化疗试验最终生存结果
讲者：Sherko Kuemmel，German Medical Institute，Limassol，Germany
LB1-06:Primary results of SOLTI VALENTINE:neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive(HR+)/HER2-negative(neg)early breast cancer(EBC).
SOLTI VALENTINE研究的主要结果：针对高风险HR+/HER2-早期乳腺癌（EBC），比较单独使用HER3-DXd或联合使用来曲唑新辅助治疗的随机II期试验
讲者：Mafalda Oliveira，Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology(VHIO)，Barcelona，Spain
LB1-07:Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.
3期KEYNOTE-522研究生物标志物探索性分析：对早期TNBC患者用帕博利珠单抗或安慰剂联合化疗进行新辅助治疗，随后用帕博利珠单抗或安慰剂进行辅助治疗
讲者：Joyce O’Shaughnessy，Baylor-Sammons Cancer Center，Dallas，Texas
General Session 1
时间：12月11日9:15–11:30 am
地点：Hall 1
GS1-01:Imlunestrant，an Oral Selective Estrogen Receptor Degrader(SERD)，as Monotherapy and Combined with Abemaciclib，for Patients w/ER+，HER2-Advanced Breast Cancer(ABC)，Pretreated w/Endocrine Therapy(ET):Results of the Phase 3 EMBER-3 trial.
口服选择性雌激素受体降解剂（SERD）Imlunestrant单药治疗及联合阿贝西利治疗既往接受内分泌治疗（ET）的雌激素受体阳性（ER+）、人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）患者的疗效：III期EMBER-3研究结果
讲者：Komal Jhaveri，Memorial Sloan Kettering Cancer Center，New York，New York
GS1-03:Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer(mBC):prespecified final analysis of progression-free survival(PFS)of the phase 3 PHILA trial.
吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛用于未接受过治疗的HER2阳性转移性乳腺癌（mBC）：III期PHILA试验预设的无进展生存期（PFS）最终分析
讲者：徐兵河（中国医学科学院肿瘤医院）
GS1-04:HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer:a Prospective，Randomized，Open-label，Phase 2 Trial.
靶向HER2的抗体-药物偶联物SHR-A1811用于HER2阳性早期乳腺癌的新辅助治疗：一项前瞻性、随机、开放标签的2期试验
讲者：李俊杰（复旦大学附属肿瘤医院）
GS1-06:PRO B–a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients.
PRO B——一项评估转移性乳腺癌患者症状监测效果的优效性随机对照试验
讲者：Maria Margarete Karsten，Charité-Universitätsmedizin，Berlin
GS1-08:Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer:results from an international cohort study.
年轻乳腺癌患者中BRCA携带者接受降低风险性手术与生存期之间的关联：一项国际队列研究结果
讲者：Matteo Lambertini，University of Genova，Genova，Italy
GS1-09:OlympiA-Phase 3，multicenter，randomized，placebo-controlled trial of adjuvant olaparib after(neo)adjuvant chemotherapy in patients w/germline BRCA1/BRCA2 pathogenic variants&high risk HER2-negative primary breast cancer;longer term follow.
OlympiA长期随访——一项针对携带胚系BRCA1/BRCA2致病性变异且高危HER2阴性原发性乳腺癌患者，在（新）辅助化疗后使用辅助奥拉帕利（olaparib）的III期、多中心、随机、安慰剂对照试验
讲者：Judy Garber，Dana-Farber Cancer Institute，Boston，Massachusetts
Rapid Fire 1
时间：12月11日12:00–12:50 pm
地点：Stars at Night 1-2
主持人：Moderator:Shom Goel，University of Melbourne Peter MacCallum Cancer Centre
RF1-01:Effect of a weight loss intervention(WLI)on metabolic and inflammatory biomarkers in women with obesity and breast cancer:Results from the Breast Cancer Weight Loss(BWEL)Trial(Alliance).
减重干预（WLI）对肥胖合并乳腺癌女性的代谢和炎症生物标志物的影响：乳腺癌减重（BWEL）试验（Alliance）的结果
讲者：Jennifer Ligibel，Dana-Farber Cancer Institute，Boston，Massachusetts
RF1-02:Palbociclib plus letrozole versus weekly paclitaxel，both in combination w/trastuzumab plus pertuzumab，as neoadjuvant treatment for patients w/HR+/HER2+early breast cancer:primary results from the randomized phase II TOUCH trial(IBCSG 55-17).
哌柏西利联合来曲唑对比周疗紫杉醇，两者均与曲妥珠单抗和帕妥珠单抗联用，作为HR+/HER2+早期乳腺癌患者的新辅助治疗：来自II期TOUCH随机试验（IBCSG 55-17）的主要结果
讲者：Luca Malorni，USL Toscana Centro，Hospital of Prato，Prato，Italy
RF1-03:Three-year event-free survival(EFS)of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer(BOOG 2018-01).
多中心II期TRAIN-3研究评估了II期和III期HER2阳性乳腺癌（BOOG 2018-01）中基于影像引导的新辅助化疗持续时间优化的三年无事件生存率（EFS）
讲者：Fleur Louis，Antoni van Leeuwenhoekziekenhuis，Amsterdam，Netherlands
RF1-04:Long-Term Follow-up and updated analysis from S0221，Comparing Alternative Dose-Schedules of Adjuvant Anthracycline/Taxane Therapy in High-Risk Early Breast Cancer.
S0221研究长期随访与更新分析：比较蒽环类/紫杉类辅助治疗高危早期乳腺癌的替代剂量方案
讲者：Azka Ali，Rosalind Franklin University of Medicine and Science，North Chicago，Illinois
RF1-05:DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer，and healthy controls.
同侧与对侧乳房的良性组织中的DNA甲基化模式相似，但与配对的乳腺癌组织和健康对照组存在差异
讲者：Saya Dennis，Northwestern University Feinberg School of Medicine，Chicago，Illinois
RF1-06:Association of polygenic-based breast cancer risk prediction with patient management.
基于多基因的乳腺癌风险预测与患者管理的相关性
讲者：Katie Johansen Taber，Myriad Genetics，San Francisco，California
RF1-07:Multifactor analysis for pathologic complete response(pCR)in a chemotherapy-free regimen of durvalumab，trastuzumab，and pertuzumab(DTP Trial)in HER2-enriched early breast cancer.
在HER2过表达的早期乳腺癌中，不含化疗的度伐利尤单抗、曲妥珠单抗和帕妥珠单抗方案（DTP研究）的病理完全缓解（pCR）的多因素分析
讲者：Bojana Stefanovska，UT Health Science Center，San Antonio，Texas
General Session 2
时间：12月12日9:00–11:45 am
地点：Hall 1
GS2-01:Exclusive endocrine therapy or radiation therapy in women aged 70+years with luminal-like early breast cancer(EUROPA):preplanned interim analysis of a randomized phase 3 trial.
随机3期EUROPA研究预先计划的期中分析：70岁以上luminal型早期乳腺癌女性患者单纯内分泌治疗或放疗的疗效
讲者：Icro Meattini，University of Florence，Florence，Italy
GS2-02:Impact of Tamoxifen Only after Breast Conservation Surgery for"Good Risk"Duct Carcinoma in Situ:Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial
“低风险”原位导管癌保乳术后仅采用他莫昔芬治疗的影响：NRG Oncology/RTOG 9804和ECOG-ACRIN E5194试验的结果
讲者：Jean Wright，University of North Carolina School of Medicine，Chapel Hill，North Carolina
GS2-03:Does postmastectomy radiotherapy in’intermediate-risk’breast cancer impact overall survival?10-year results of the BIG 2-04 MRC SUPREMO randomised trial:on behalf of the SUPREMO trial investigators.
“中危”乳腺癌患者术后放疗是否影响总生存期？BIG 2-04 MRC SUPREMO随机试验10年结果：代表SUPREMO试验研究者
讲者：Ian Kunkler，Edinburgh Cancer Centre，University of Edinburgh，Edinburgh，Scotland
GS2-05:Early Oncologic Outcomes Following Active Monitoring or Surgery(+/-Radiation)for Low Risk DCIS:the Comparing an Operation to Monitoring，with or without Endocrine Therapy(COMET)Study(AFT-25).
低危导管原位癌（DCIS）患者主动监测或手术（±放疗）后的早期肿瘤学结局：比较手术与监测伴或不伴内分泌治疗（COMET）研究（AFT-25）
讲者：Eun-Sil Hwang，Duke University School of Medicine，Durham，North Carolina
GS2-06:Patient Reported Outcomes Following Active Monitoring or Surgery(+/-Radiation)for Low Risk DCIS in the Comparing an Operation to Monitoring，with or without Endocrine Therapy(COMET)Study(AFT-25).
低危导管原位癌（DCIS）患者主动监测或手术（±放疗）后的患者报告结局：比较手术与监测伴或不伴内分泌治疗（COMET）研究（AFT-25）
讲者：Ann Partridge，Dana-Farber Cancer Institute，Boston，Massachusetts
GS2-07:No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery:Final primary results of the Intergroup-Sentinel-Mamma(INSEMA)trial.
早期浸润性乳腺癌患者不接受腋窝手术vs接受保乳手术的腋窝前哨淋巴结活检比较：INSEMA（intergroup sentinel-mamma）试验的最终主要结果
讲者：Toralf Reimer，Universitätsmedizin Rostock，Rostock，Germany
GS2-09:Overweight，obesity and prognosis in 206，904 women in the Early Breast Cancer Trialists’Collaborative Group(EBCTCG)database.
早期乳腺癌试验协作组（Early Breast Cancer trials’Collaborative Group，EBCTCG）数据库中206904名女性的超重、肥胖和预后情况
讲者：Hongchao Pan，University of Oxford，Oxford，United Kingdom
GS2-10:A long-term image-derived AI risk model for primary prevention of breast cancer.
用于乳腺癌一级预防的基于长期图像衍生的AI风险模型
讲者：Mikael Eriksson，Karolinska Institutet，Solna，Sweden
GS2-11:APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.
APOBEC3突变诱导乳腺癌中促进耐药的基因组改变
讲者：Avantika Gupta，Memorial Sloan Kettering Cancer Center，New York，New York
Rapid Fire 2
时间：12月12日12:00–12:50 pm
地点：Hall 1
主持人：Carlos Arteaga，UT Southwestern，Dallas，Texas
RF2-01:Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial.
Alliance A011202临床试验纳入的新辅助化疗后残留淋巴结阳性乳腺癌患者中，腋窝清扫术对额外淋巴结病变和病理性淋巴结分期上调的影响因素
讲者：Judy Boughey，Mayo Clinic，Rochester，Minnesota
RF2-02:Axillary surgery after neoadjuvant systemic therapy(NST)for early-stage breast cancer–Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies.
早期乳腺癌新辅助全身治疗（NST）后的腋窝手术——5项新辅助治疗研究中残留微转移的治疗路径和预后影响
讲者：Johannes Holtschmidt，VP Medicine&Research GBG Forschungs GmbH
RF2-03:Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients–results from the prospective AXSANA registry trial(NCT04373655).
初诊淋巴结阳性乳腺癌患者新辅助化疗后行腋窝超声的诊断效能——来自前瞻性AXSANA注册试验（NCT04373655）的结果
讲者：Steffi Hartmann，University of Rostock，Rostock，Germany
RF2-04:Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients.One-year cosmetic outcomes of a randomized，controlled，phase 3 trial(ULTIMO).
乳腺癌患者全乳放疗后超大分割vs常规分割序贯加量疗效对比：一项随机、对照、3期试验（ULTIMO）1年美容效果
讲者：Melanie Machiels，Universiteit Antwerpen，Antwerp，Belgium
RF2-05:Validation of the association between TILs，ER status and benefit of radiotherapy in node positive，breast cancer patients:a DBCG study.
DBCG研究：验证TILs、ER状态与淋巴结阳性乳腺癌患者放疗获益之间的关系
讲者：DemetÖzcan，Aarhus University Hospital，Aarhus，Denmark
RF2-06:A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices.
一项全国性、双盲、III期、随机对照试验（RCT），比较NCORP社区实践中奥氮平和丙氯拉嗪治疗化疗导致的难治性恶心
讲者：Luke Peppone，University of Rochester Medical Center，Rochester，New York
General Session 3
时间：12月13日9:00–11:45 am
地点：Hall 1
GS3-01:Circulating tumor DNA surveillance in ZEST，a randomized，phase 3，double-blind study of niraparib or placebo in patients w/triple-negative breast cancer or HER2+BRCA-mutated breast cancer with molecular residual disease after definitive therapy.
ZEST是一项随机、3期、双盲研究，在尼拉帕利或安慰剂进行根治性治疗后有分子残留病变的三阴性乳腺癌或HER2+BRCA突变乳腺癌患者中对循环肿瘤DNA进行监测。
讲者：Nicholas Turner，Ralph Lauren Centre for Breast Cancer Research，London，United Kingdom
GS3-03:Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2-Breast Cancer.
蒽环类药物对高基因组风险淋巴结阴性HR+/HER2-乳腺癌的影响
讲者：Nan Chen，University of Chicago Medicine，Chicago，Illinois
GS3-04:(Neo)adjuvant nab-PAC weekly vs sb-PAC q2w，followed by EC q2w，in genomically or clinically high-risk HR+/HER2-early breast cancer according to ET-response:final survival results from the WSG ADAPT-HR+/HER2-chemotherapy-trial.
在遗传或临床高危HR+/HER2-早期乳腺癌中，根据ET反应（新）辅助nab-PAC周疗vs每2周1次sb-PAC，随后每2周1次EC：WSG ADAPT-HR+/HER2-化疗试验最终生存结果
讲者：Sherko Kuemmel，German Medical Institute，Berlin，Germany
GS3-05:NSABP B-59/GBG-96-GeparDouze:A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer.
NSABP B-59/GBG-96-GeparDouze：一项针对II期和III期三阴性乳腺癌患者的随机双盲III期临床试验，比较新辅助化疗联合阿替利珠单抗或安慰剂，随后辅助使用阿替利珠单抗或安慰剂的效果
讲者：Charles Geyer，University of Pittsburgh，Pittsburgh，Pennsylvania
GS3-06:Neoadjuvant camrelizumab plus chemotherapy(chemo)for early or locally advanced triple-negative breast cancer(TNBC):a randomized，double-blind，phase 3 trial.
卡瑞利珠单抗联合化疗（chemo）新辅助治疗早期或局部晚期三阴性乳腺癌（TNBC）：一项随机、双盲、3期试验
讲者：邵志敏（复旦大学附属肿瘤医院）
GS3-08:In situ detection of individual classical MHC-I gene products in breast cancer identifies gene-and subtype-specific biased antigen presentation loss.
在乳腺癌中原位检测单个经典MHC-I基因产物，可识别出基因和亚型特异性的特异性抗原呈递缺失
讲者：Paula Gonzalez-Ericsson，Vanderbilt-Ingram Cancer Center，Nashville，Tennessee
GS3-09:Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2-metastatic breast cancer.
真实世界临床和基因组数据的多模态整合用于预测CDK4/6抑制剂在HR+/HER2-转移性乳腺癌患者中的结局
讲者：Enrico Moiso，Memorial Sloan Kettering Cancer Center，New York，New York
GS3-10:Paired DNA and RNA analysis of CALGB 40603(Alliance)reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer.
配对的DNA和RNA分析CALGB 40603（Alliance）揭示了II-III期三阴性乳腺癌的分子和预后特征
讲者：Brooke Felsheim，UNC School of Medicine，Chapel Hill，North Carolina
Rapid Fire 3
时间：12月13日12:00–12:50 pm
地点：Hall 1
主持人：Peter Fasching，University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN，Germany
RF3-01:TBCRC 056:A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA-or PALB2-mutated breast cancer:Results from the ER+/HER2-cohort.
TBCRC 056研究ER+/HER2-队列的结果：一项尼拉帕利联合dostarlimab新辅助治疗BRCA突变或PALB2突变乳腺癌患者的II期研究
讲者：Erica Mayer，Dana-Farber Cancer Institute，Boston，Massachusetts
RF3-02:Efficacy of adjuvant avelumab by PD-L1，tumor infiltrating lymphocytes and residual cancer burden in high-risk triple negative breast cancer:secondary and exploratory endpoints of the phase III A-BRAVE trial.
基于PD-L1、肿瘤浸润淋巴细胞和残余肿瘤负荷对高危三阴性乳腺癌进行阿维鲁单抗辅助治疗的疗效：III期A-BRAVE研究的次要和探索性终点
讲者：Maria Vittoria Dieci，University of Padua，Padua，Italy
RF3-03:Nivolumab+Ipilimumab(NIVO+IPI)compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy–Final results of BreastImmune-03，a multicenter randomized open-label phase II trial.
纳武利尤单抗+伊匹木单抗（NIVO+IPI）与卡培他滨在新辅助化疗后有残留病变的三阴性乳腺癌患者中的疗效比较——多中心随机开放标签II期试验BreastImmune-03的最终结果
讲者：Olivier Trédan，Centre Lèon Bèrard，Lyon，France
RF3-04:NRG-BR004:A Randomized，Double-blind，Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer.
NRG-BR004：紫杉烷/曲妥珠单抗/帕妥珠单抗联合阿替利珠单抗或安慰剂一线治疗HER2阳性转移性乳腺癌的随机、双盲、III期试验
讲者：Vicente Valero，MD Anderson Cancer Center，Houston，Texas
RF3-05:A Phase 2 Study of Neoadjuvant HER2-targeted Therapy+/-Immunotherapy with Pembrolizumab(neoHIP).
新辅助HER2靶向治疗±帕博利珠单抗免疫治疗的2期研究（neoHIP）
讲者：Heather McArthur，UT Southwestern Medical Center，Dallas，Texas
RF3-06:Mepitel Film for the Reduction of Radiation Dermatitis in Post-mastectomy Radiation Therapy:Results from Alliance A221803:A Multicenter Phase III Randomized Clinical Trial
Mepitel贴膜在减少乳腺癌术后放疗所致放射性皮炎中的应用：Alliance A221803多中心III期随机临床试验结果
讲者：Kimberly Corbin，Mayo Clinic，Rochester，Minnesota
RF3-07:ROSCO:Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer:A randomised phase III，stratified biomarker trial of neoadjuvant 5-Fluorouracil，Epirubicin&Cyclophosphamide vs Docetaxel&Cyclophosphamide chemotherapy.
ROSCO研究：随机III期、分层生物标志物试验，比较新辅助5-氟尿嘧啶、表柔比星与环磷酰胺vs多西他赛和环磷酰胺化疗方案，评估可手术乳腺癌新辅助化疗最优选择反应。
讲者：Daniel Rea，University of Birmingham，Birmingham，United Kingdom
Poster Spotlight Sessions
▌Concurrent Poster Spotlight Sessions 1，3-5，7
Session 1:New Insights into Immune Biomarkers（免疫生物标志物的新见解）
时间：12月11日7:00–8:30 am
地点：Room 221ABC
主持人：David Rimm，Yale University
Session 3:Highlights on Novel Therapeutics（新型治疗亮点）
时间：12月11日7:00–8:30 am
地点：Stars at Night 1-2
主持人：Sara Tolaney，Dana-Farber Cancer Institute
Session 4:Prediction of Chemotherapy Response（化疗疗效预测）
时间：12月11日7:00–8:30 am
地点：Stars at Night 3-4
主持人：Sherene Loi，Peter Macallum Cancer Centre
Session 5:The Heart of the Matter-Improving Adverse Effects（核心问题-改善不良反应）
时间：12月11日7:00–8:30 am
地点：Hemisfair Ballroom 3
主持人：Anne Blaes，Masonic Cancer Center University of Minnesota
Session 7:Targeting the ER and PI3K pathway:Novel drugs and combinations（靶向ER和PI3K通路：新型药物和组合）
时间：12月11日7:00–8:30 am
地点：Hemisfair Ballroom 1-2
主持人：Shom Goel，Peter MacCallum Cancer Centre
▌Concurrent Poster Spotlight Sessions 2，6，8，9 and 15
Session 2:Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer:Survival，QOL and biomarkers（转移性乳腺癌患者的个体化CDK 4/6抑制剂治疗：生存期、生活质量和生物标志物）
时间：12月12日7:00–8:30 am
地点：Hemisfair Ballroom 1-2
主持人：Lisa Carey，Lineberger Comprehensive Cancer Center University of North Carolina
Session 6:Locoregional Therapy（局部区域治疗）
时间：12月12日7:00–8:30 am
地点：Room 221ABC
主持人：Mylin Torres，Winshop Cancer Institute of Emory University
Session 8:Novel HER2 Therapeutics（新型HER2治疗）
时间：12月12日7:00–8:30 am
地点：Stars at Night 1-2
主持人：Ian Krop，Yale School of Medicine
Session 9:ctDNA uses for Minimal Residual Disease testing，tumor evolution，and novel technologies（ctDNA用于微小残留病检测、肿瘤进化和新技术）
时间：12月12日7:00–8:30 am
地点：Stars at Night 3-4
主持人：Charles Perou，Lineberger Comprehensive Cancer Center University of North Carolina
Session 15:Survivorship–Biomarker predictors and other survival-associated factors（生存-生物标志物预测和其他生存相关因素）
时间：12月12日7:00–8:30 am
地点：Room 221ABC
主持人：Lindsay Peterson，Washington University Siteman Cancer Center，St.Louis，Missouri
▌Concurrent Poster Spotlight Sessions 10-14
Session 10:Addressing Racial Disparities in Breast Cancer Outcomes（探讨乳腺癌结局的种族差异）
时间：12月13日7:00–8:30 am
地点：Hemisfair Ballroom 3
主持人：Yara Abdou，University of North Carolina School of Medicine
Session 11:Imaging to Guide Breast Cancer Treatment–Molecular Imaging and AI（影像学指导乳腺癌治疗——分子影像学和人工智能）
时间：12月13日7:00–8:30 am
地点：Hemisfair Ballroom 1-2
主持人：David Mankoff，Perelman School of Medicine University of Pennsylvania
Session 12:Immunobiology Impact on Therapeutic Efficacy（免疫生物学对治疗效果的影响）
时间：12月13日7:00–8:30 am
地点：Room 221ABC
主持人：Lajos Pusztai，Yale School of Medicine，New Haven，Connecticut
Session 13:Molecular determinants of therapeutic response and resistance-Spotight on CDK 4/6i and ADCs（治疗反应和耐药的分子决定因素——聚焦CDK4/6i和ADCs）
时间：12月13日7:00–8:30 am
地点：Stars at Night 1-2
主持人：Aditya Bardia，UCLA David Geffen School of Medicine，Los Angeles，California
Session 14:Brain Metastasis（脑转移）
时间：12月13日7:00–8:30 am
地点：Stars at Night 3-4
主持人：William Gradishar，Northwestern University Feinberg School of Medicine，Chicago，Illinois
京公网安备 11010502033352号